- DSc, University of Warwick (1989)
- PhD, Department of Biochemistry, University of Toronto (1970)
- MSc, Molecular Enzymology, University of Warwick (1967)
- MA, Chemistry, University of Cambridge (1965)
- American Association for Cancer Research
- American Society for Nutrition
- Canadian Society for Nutritional Sciences
- Society of Toxicology
- Society of Toxicology of Canada
Note: Dr. Archer's research program is no longer active.
Other Academic Appointments
Professor Emeritus, Department of Medical Biophysics, Temerty Faculty of Medicine, University of Toronto
About Dr. Michael Archer
Dr. Michael Archer received an MA in 1965 in chemistry from the University of Cambridge, an MSc in 1967 in molecular enzymology from the University of Warwick, and a PhD in 1970 in biochemistry from the University of Toronto. He was a postdoctoral fellow at the Massachusetts Institute of Technology where he was subsequently appointed Assistant then Associate Professor in the Department of Applied Biological Sciences. During this time, Dr. Archer was the recipient of a Research Career Development Award from the NIH. He returned to the University of Toronto in 1979 as a Senior Scientist at the Ontario Cancer Institute/Princess Margaret Hospital with a faculty position in the Department of Medical Biophysics. In 1994 he was awarded an NSERC - Industry Research Chair in Nutritional Toxicology in the Department of Nutritional Sciences and from 1998 – 2009 he was Earle W. McHenry Professor and Chair of that Department. He is currently a Professor Emeritus. Dr. Archer’s research on environmental and genetic mechanisms of cancer development has led to over 200 scientific publications. In 1989, he was awarded a DSc degree from the University of Warwick for his contributions to cancer research.
Honours and Distinctions (Selected)
Research Chair in Nutritional Toxicology, Natural Sciences and Engineering Research Council (1994)
Future Leader Award, International Life Sciences Institute (1974)
Research Career Development Award, National Institutes of Health (1977-82)
Fellow of the Royal Society of Chemistry, London (1977)
- Mullen PJ, Yu R, Longo J, Archer MC, Penn LZ. The interplay between cell signalling and the mevalonate pathway in cancer. Nat Rev Cancer. 2016 Nov;16(11):718-731. doi: 10.1038/nrc.2016.76. Epub 2016 Aug 26. PMID: 27562463.
- Yang K, Fard S, Furrer R, Archer MC, Bruce WR, Lip H, Mehta R, O'Brien PJ, Giacca A, Ward WE, Femia AP, Caderni G, Medline A, Banks K. Risk factors for colorectal cancer in man induce aberrant crypt foci in rats: Preliminary findings. Nutr Cancer. 2016;68(1):94-104. doi: 10.1080/01635581.2016.1115098. Epub 2015 Dec 28. PMID: 26709971; PMCID: PMC4784512.
- Menezes ME, Shen XN, Das SK, Emdad L, Guo C, Yuan F, Li YJ, Archer MC, Zacksenhaus E, Windle JJ, Subler MA, Ben-David Y, Sarkar D, Wang XY, Fisher PB. MDA-7/IL-24 functions as a tumor suppressor gene in vivo in transgenic mouse models of breast cancer. Oncotarget. 2015 Nov 10;6(35):36928-42. doi: 10.18632/oncotarget.6047. PMID: 26474456; PMCID: PMC4741906.
- Li YJ, Liu G, Xia L, Xiao X, Liu JC, Menezes ME, Das SK, Emdad L, Sarkar D, Fisher PB, Archer MC, Zacksenhaus E, Ben-David Y. Suppression of Her2/Neu mammary tumor development in mda-7/IL-24 transgenic mice. Oncotarget. 2015 Nov 10;6(35):36943-54. doi: 10.18632/oncotarget.6046. PMID: 26460950; PMCID: PMC4741907.
- Hopperton KE, Duncan RE, Bazinet RP, Archer MC. Fatty acid synthase plays a role in cancer metabolism beyond providing fatty acids for phospholipid synthesis or sustaining elevations in glycolytic activity. Exp Cell Res. 2014 Jan 15;320(2):302-10. doi: 10.1016/j.yexcr.2013.10.016. Epub 2013 Nov 4. PMID: 24200503.